Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit

Executive Summary

Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.
Advertisement

Related Content

BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending
BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending
Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
Advertisement
UsernamePublicRestriction

Register

PS038173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel